T-cell Receptor– tag –
-
TScan Therapeutics Pivots to In Vivo TCR-T Therapy, Halting Allogeneic Cell Program TSC-101 Amidst Manufacturing Challenges
FirstWord Pharma USA Overview TScan Therapeutics announced a strategic pivot, discontinuing its lead allogeneic cell therapy program, TSC-101, and shifting focus to preclinical in vivo TCR-T candidates for solid tumors, citing funding co... -
Catalent Bolsters End-to-End CDMO Services for Autologous & Allogeneic Cell Therapies, Including iPSC Center of Excellence
Catalent USA Overview Catalent is enhancing its end-to-end CDMO manufacturing support and process development services for both autologous and allogeneic cell therapies, covering CAR-T, TCR, TIL, NK cells, and iPSC- and MSC-derived treat... -
Kincell Bio Inaugurates and Expands State-of-the-Art GMP Cell Therapy Manufacturing Facilities in Gainesville and Research Triangle Park
Kincell Bio USA Overview Kincell Bio has opened and expanded GMP cell therapy manufacturing facilities in Gainesville, Florida, and Research Triangle Park, North Carolina, designed to support both autologous and allogeneic cell therapies... -
Kincell Bio Strengthens GMP Manufacturing for Autologous & Allogeneic Cell Therapies Across Diverse Modalities from US Two Sites
Kincell Bio USA Overview Kincell Bio announced enhanced GMP manufacturing services for both autologous and allogeneic cell therapy programs, leveraging two advanced facilities in Gainesville, Florida, and Research Triangle Park, North Ca... -
Miltenyi Biotec’s Global T-Cell Manufacturing Platform Integrates Automated Closed Systems, Cuts Manual Labor by Over 70%, Achieves High Yields
Bioprocess Online Germany Overview Miltenyi Biotec proposes that global scaling of TCR-T cell manufacturing requires a fundamental process redesign, integrating six key production steps into a single automated, closed system. This integr... -
Cellares and TScan Therapeutics Partner to Automate Manufacturing of TCR-T Therapy Candidate TSC-101 for Hematologic Malignancies, Accelerating Commercialization
OTC Markets (BusinessWire) USA Overview Cellares and TScan Therapeutics announced an agreement to evaluate the automated manufacturing of TSC-101, a TCR-T cell therapy candidate for patients with hematologic malignancies. This collaborat... -
Aldevron and Minaris Renew Lentiviral Plasmid Agreement, Bolstering Critical Supply for Advanced Cell and Gene Therapies
BioBuzz USA Overview Aldevron and Minaris have renewed their lentiviral plasmid licensing agreement, significantly expanding access to scalable plasmid solutions essential for advanced cell and gene therapy (CGT) developers. This collabo...
1